HK1248070A1 - 作为激酶抑制剂的杂环化合物 - Google Patents

作为激酶抑制剂的杂环化合物 Download PDF

Info

Publication number
HK1248070A1
HK1248070A1 HK18107657.9A HK18107657A HK1248070A1 HK 1248070 A1 HK1248070 A1 HK 1248070A1 HK 18107657 A HK18107657 A HK 18107657A HK 1248070 A1 HK1248070 A1 HK 1248070A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
cycloalkyl
cancer
group
compound
Prior art date
Application number
HK18107657.9A
Other languages
English (en)
Chinese (zh)
Inventor
T‧王
S‧盖特利
S‧蓋特利
Original Assignee
转化药物开发有限责任公司
轉化藥物開發有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 转化药物开发有限责任公司, 轉化藥物開發有限責任公司 filed Critical 转化药物开发有限责任公司
Publication of HK1248070A1 publication Critical patent/HK1248070A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK18107657.9A 2015-05-18 2016-05-18 作为激酶抑制剂的杂环化合物 HK1248070A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163369P 2015-05-18 2015-05-18
US62/163,369 2015-05-18
US201562203070P 2015-08-10 2015-08-10
US62/203,070 2015-08-10
PCT/US2016/033111 WO2016187324A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1248070A1 true HK1248070A1 (zh) 2018-10-12

Family

ID=57320732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107657.9A HK1248070A1 (zh) 2015-05-18 2016-05-18 作为激酶抑制剂的杂环化合物

Country Status (9)

Country Link
US (3) US10392402B2 (enExample)
EP (1) EP3297437A4 (enExample)
JP (1) JP2018515623A (enExample)
CN (1) CN107835637A (enExample)
AU (1) AU2016264220A1 (enExample)
CA (1) CA3024113A1 (enExample)
HK (1) HK1248070A1 (enExample)
IL (1) IL255750A (enExample)
WO (1) WO2016187324A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
WO2018094362A1 (en) 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
JP7490569B2 (ja) * 2018-04-24 2024-05-27 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物、組成物および処置方法
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
CN113121443B (zh) 2019-12-31 2024-07-09 财团法人工业技术研究院 β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途
AU2021206651B2 (en) * 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
KR20240176853A (ko) * 2023-06-15 2024-12-26 현대자동차주식회사 이중 전원 공급 장치, 그를 포함한 시스템 및 그 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
EP2234487A4 (en) 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
US20090258907A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9221808B2 (en) * 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9284298B2 (en) * 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors

Also Published As

Publication number Publication date
CA3024113A1 (en) 2016-11-24
US20200255448A1 (en) 2020-08-13
JP2018515623A (ja) 2018-06-14
AU2016264220A1 (en) 2018-01-04
US10633393B2 (en) 2020-04-28
IL255750A (en) 2018-01-31
WO2016187324A1 (en) 2016-11-24
US20180141959A1 (en) 2018-05-24
US10392402B2 (en) 2019-08-27
CN107835637A (zh) 2018-03-23
EP3297437A4 (en) 2019-02-27
US20200017520A1 (en) 2020-01-16
EP3297437A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
US10633393B2 (en) Heterocyclic compounds as kinase inhibitors
US10807966B2 (en) Heterocyclic compounds as kinase inhibitors
AU2017259436B2 (en) Piperidines as menin inhibitors
EP1370553B1 (en) Rho-kinase inhibitors
JP4505228B2 (ja) Ｒｈｏ−キナーゼ阻害剤
SG182187A1 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
CA2777762A1 (en) Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon
CA2688326C (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
US20100324041A1 (en) Pyrrolopyridines as kinase inhibitors
CA3168222A1 (en) Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient
AU2012214265A1 (en) Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
CN110099906B (zh) 作为激酶抑制剂的酰胺化合物
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN101253167A (zh) 作为ksp抑制剂的取代的咪唑化合物
WO2021115432A1 (zh) 新型含喹唑啉类化合物及其中间体与应用
US20140221370A1 (en) Pyrrolopyridines as kinase inhibitors
CN120457107A (zh) Sarm1调节剂、其制备和用途
HK40013991A (en) Heterocyclic compounds as kinase inhibitors
TW202023548A (zh) 新穎噻唑衍生物以及其藥用可接受鹽類
EP3640242A1 (en) Rock-inhibiting compound and uses thereof
WO2024120519A1 (zh) Tead抑制剂、其制备方法和在医学上的应用
BR112020013759A2 (pt) triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho
HK40010105B (en) Amide compounds as kinase inhibitors
HK40010105A (en) Amide compounds as kinase inhibitors
HK1061030B (en) Rho-kinase inhibitors